Treatment(s) already received-None Page 2 Posts on Medivizor
Navigation Menu

Treatment(s) already received-None Posts on Medivizor

Looking for patients with small lymphocytic lymphoma to test acalabrutinib-obinutuzumab combination

Posted by on Apr 22, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 2 trial is evaluating the effectiveness of acalabrutinib (Calquence) with or without obinutuzumab (Gazyva) for small lymphocytic lymphoma (SLL). The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer. This study is being conducted in Phoenix, Arizona, Jacksonville,...

Read More

Evaluating PCR therapy for previously untreated indolent non-Hodgkin’s lymphoma

Posted by on Mar 31, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the long-term effectiveness and safety of a new chemotherapy regimen in patients with previously untreated indolent (painless) non-Hodgkin’s lymphoma (NHL). This study concluded that this regimen is effective and well-tolerated for these patients. Some background There are three common types of painless NHL....

Read More

Looking for children and young adults with Hodgkin lymphoma to test a new treatment.

Posted by on Mar 28, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This trial is examining the safety and effectiveness of pembrolizumab (Keytruda) in the treatment of children and young adults with classical Hodgkin lymphoma (HL). The main outcome to be measured will be a response to treatment. This trial is recruiting in the Republic of Korea and the United States. The details...

Read More

Searching for patients to try a new combination of treatments for Hodgkin lymphoma.

Posted by on Mar 26, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This trial is investigating the effects of AVD [doxorubicin (Adriamycin), vinblastine (Velban), and dacarbazine (DTIC)] with brentuximab vedotin (Adcetris) induction chemotherapy, plus nivolumab (Opdivo) for Hodgkin lymphoma (HL). The main outcome to be measured is survival without cancer worsening 3 years after treatment. The details...

Read More

Searching for patients with newly-diagnosed AML to try this new treatment option

Posted by on Mar 15, 2019 in Leukemia | 0 comments

In a nutshell This Phase 3 study is evaluating the safety and effectiveness of midostaurin (Rydapt) combined with chemotherapy for patients with newly-diagnosed acute myeloid leukemia (AML). The main outcome to be measured will be event-free survival at 5 years. The details Previous studies have shown that midostaurin combined with chemotherapy is...

Read More

Searching for patients with previously untreated DLBCL to try this new treatment combination

Posted by on Mar 15, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study is comparing the effectiveness of R-CHOP chemotherapy with or without enzastaurin (Kinenza) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). The main outcome to be measured will be overall survival at the end of the study. The details The current standard first-line treatment for DLBCL is R-CHOP...

Read More

Looking at different types of radiation therapy for intermediate risk prostate cancer

Posted by on Feb 23, 2019 in Prostate cancer | 0 comments

In a nutshell This trial evaluates the effectiveness of radiation therapy delivered from outside the body for the treatment of prostate cancer. The main outcomes of this trial are the number of patients who have no damage to genital or urinary organs and survival without cancer. This trial is taking place in various sites across the USA and...

Read More

Looking for men with newly diagnosed prostate cancer to test an immune based therapy, Sipuleucel-T

Posted by on Feb 9, 2019 in Prostate cancer | 0 comments

In a nutshell This study evaluates the effectiveness of an immunotherapy in the treatment of newly diagnosed prostate cancer. The main outcome to be measured in this trial is the number of patients whose cancer does not progress within 3 years after immunotherapy injection. This trial is taking place in many sites across the USA.  The details...

Read More

Searching for patients to test venetoclax with azacitidine treatment for acute myeloid leukemia

Posted by on Jan 27, 2019 in Leukemia | 0 comments

In a nutshell This trial is comparing the safety and effectiveness of venetoclax (Venclexta) and azacitidine (Vidaza) with azacitidine alone in patients with acute myeloid leukemia (AML). The main outcome to be measured will be overall survival. Complete remission (no signs of cancer after treatment) will also be measured. The details Acute...

Read More